Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Trial details
- Registry ID
- NCT04229979
- Phase
- Phase 3
The FDA approved Venetoclax (Venclexta) on 11 Apr 2016.
Drug identity checked against registry records
Also recorded as Venclexta; Venclexta®; Venclyxto
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Sellas Life Sciences Group | Phase 3 | Active not recruiting | 2025-12Estimated |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805 | TGTX | Phase 2 | Terminated | 2022-05-22Actual |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312 | KURA | Phase 3 | Recruiting | 2031-11Estimated |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525 | TGTX | Phase 2, Phase 3 | Terminated | 2022-12-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2016-04-11Day | Venetoclax | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208573", "applicant_as_listed_by_fda": "ABBVIE", "brand_names": ["VENCLEXTA"], "active_ingredients": ["VENETOCLAX"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160411", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |